Werewolf Therapeutics appoints Meeta Chatterjee, Ph.D. to Board

Werewolf Therapeutics, Inc.

Dr. Chatterjee appointed as Class II director, term until 2023 annual meeting.
She is Senior VP of Global Business Development at Legend Biotech; previously at Merck.
Receives $35,000 annual cash, $4,000 committee retainer, plus option grant of 23,200 shares at $15.97.
Appointed to Nominating and Corporate Governance Committee.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Meeta Chatterjee, Ph.D.

Director

HOWL · Werewolf Therapeutics, Inc.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

On October 28, 2021, the Board of Directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Meeta Chatterjee, Ph.D., as a director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Meeta Chatterjee, Ph.D. was appointed as Director at Werewolf Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On October 28, 2021, the Board of Directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Meeta Chatterjee, Ph.D., as a director.

View on SEC.gov

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001785530-21-000043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.